Published in Hepatology on October 01, 1999
Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest (2003) 3.40
Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J Virol (2002) 1.98
Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines. BMC Bioinformatics (2007) 1.47
Five HLA-DP molecules frequently expressed in the worldwide human population share a common HLA supertypic binding specificity. J Immunol (2010) 1.29
Two successive hepatitis C virus infections in an intravenous drug user. J Clin Microbiol (2000) 1.20
Human leukocyte antigen class II DQB1*0301, DRB1*1101 alleles and spontaneous clearance of hepatitis C virus infection: a meta-analysis. World J Gastroenterol (2005) 1.11
Minimal T-cell-stimulatory sequences and spectrum of HLA restriction of immunodominant CD4+ T-cell epitopes within hepatitis C virus NS3 and NS4 proteins. J Virol (2005) 1.09
Reduction of retrovirus-induced immunosuppression by in vivo modulation of T cells during acute infection. J Virol (2004) 0.99
Immunologic evidence for lack of heterologous protection following resolution of HCV in patients with non-genotype 1 infection. Blood (2007) 0.98
T cell responses to viral infections - opportunities for Peptide vaccination. Front Immunol (2014) 0.95
Prospects for dendritic cell vaccination in persistent infection with hepatitis C virus. J Clin Virol (2004) 0.94
CD4+ T cell responses in hepatitis C virus infection. World J Gastroenterol (2007) 0.93
Antigens for CD4 and CD8 T cells in tuberculosis. Cold Spring Harb Perspect Med (2014) 0.93
Virological footprint of CD4+ T-cell responses during chronic hepatitis C virus infection. J Gen Virol (2010) 0.89
HCV genotype-3a T cell immunity: specificity, function and impact of therapy. Gut (2012) 0.86
Definition of CD4 Immunosignatures Associated with MTB. Front Immunol (2014) 0.85
Role of host genetic factors in the outcome of hepatitis C virus infection. Viruses (2009) 0.84
Evidence for lack of cross-genotype protection of CD4+ T cell responses during chronic hepatitis C virus infection. Clin Exp Immunol (2003) 0.83
Hepatitis C virus adaptation to T-cell immune pressure. ScientificWorldJournal (2013) 0.82
Glances in Immunology of HIV and HCV Infection. Adv Virol (2012) 0.82
Sequence-based in silico analysis of well studied hepatitis C virus epitopes and their variants in other genotypes (particularly genotype 5a) against South African human leukocyte antigen backgrounds. BMC Immunol (2012) 0.82
A novel, helminth-derived immunostimulant enhances human recall responses to hepatitis C virus and tetanus toxoid and is dependent on CD56+ cells for its action. Clin Exp Immunol (2008) 0.78
Identification and retrospective validation of T-cell epitopes in the hepatitis C virus genotype 4 proteome: an accelerated approach toward epitope-driven vaccine development. Hum Vaccin Immunother (2014) 0.77
TH1 cytokine response to HCV peptides in Egyptian health care workers: a pilot study. Virol J (2013) 0.76
Equivalent T cell epitope promiscuity in ecologically diverse human pathogens. PLoS One (2013) 0.76
Vaccination with dendritic cells pulsed with hepatitis C pseudo particles induces specific immune responses in mice. World J Gastroenterol (2012) 0.75
Sarcoidosis with Both Plaques and Subcutaneous Nodules Associated with Combination Therapy with Peginterferon α-2a and Ribavirin. Case Rep Dermatol Med (2011) 0.75
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol (2000) 16.83
Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature (2000) 9.80
Hepatitis B virus immunopathogenesis. Annu Rev Immunol (1995) 8.62
Structure and organization of the hepatitis C virus genome isolated from human carriers. J Virol (1991) 8.33
The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science (1987) 5.32
Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat Med (1999) 4.93
Isolation and characterization of antigen-Ia complexes involved in T cell recognition. Cell (1986) 4.71
Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature (1995) 4.68
Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature (1994) 4.42
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol (1994) 4.37
Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol (1995) 4.31
Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest (1996) 4.10
The minimal number of class II MHC-antigen complexes needed for T cell activation. Science (1990) 4.09
Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst (1999) 4.04
Complete nucleotide sequence of the Japanese encephalitis virus genome RNA. Virology (1987) 3.96
Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol (1998) 3.95
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol (2001) 3.92
Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell (1993) 3.80
The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med (2000) 3.78
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol (2002) 3.75
Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus. J Immunol (1998) 3.65
Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells. Nature (1987) 3.63
The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med (1996) 3.60
The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity (2001) 3.52
Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol (1996) 3.45
HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol (1993) 3.42
Differential effects of cytolytic T cell subsets on intracellular infection. Science (1997) 3.39
Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science (1992) 3.39
CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol (2000) 3.36
Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. J Exp Med (1998) 3.35
The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med (1995) 3.34
Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol (1990) 3.31
Disruption of the mouse RBP-J kappa gene results in early embryonic death. Development (1995) 3.30
Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell (1992) 3.24
Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med (1992) 3.11
Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest (1997) 2.99
Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest (1998) 2.97
Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity (1994) 2.90
Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med (1991) 2.88
HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci U S A (1991) 2.83
Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med (1995) 2.80
Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci U S A (1996) 2.70
Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology (1999) 2.62
Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology (1997) 2.61
Immunological self, nonself discrimination. Science (1987) 2.59
Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J Mol Biol (1997) 2.57
On the interaction of promiscuous antigenic peptides with different DR alleles. Identification of common structural motifs. J Immunol (1991) 2.49
HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis. J Exp Med (1993) 2.49
Targeted gene disruption of Hsp70-2 results in failed meiosis, germ cell apoptosis, and male infertility. Proc Natl Acad Sci U S A (1996) 2.40
Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med (1994) 2.37
Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol (1995) 2.34
Identification of Db- and Kb-restricted subdominant cytotoxic T-cell responses in lymphocytic choriomeningitis virus-infected mice. Virology (1998) 2.31
Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol (2000) 2.30
Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol (2000) 2.29
The interaction between protein-derived immunogenic peptides and Ia. Immunol Rev (1987) 2.24
Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection. J Immunol (1996) 2.24
Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med (1994) 2.18
Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med (1996) 2.17
Conserved T cell receptor repertoire in primary and memory CD8 T cell responses to an acute viral infection. J Exp Med (1998) 2.13
Definition of specific peptide motifs for four major HLA-A alleles. J Immunol (1994) 2.11
Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways. Nature (1990) 2.11
Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med (2001) 2.10
Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest (1991) 2.08
Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol (1994) 2.07
Class I-restricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo. J Immunol (1994) 2.05
Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol (1995) 2.05